Who is sponsoring NCT04760704?

NCT04760704 is sponsored by University Hospital, Lille.

What condition does NCT04760704 study?

NCT04760704 studies Covid19 Vaccine.

Is NCT04760704 still recruiting?

NCT04760704 is currently completed. Last updated 26 December 2025.

Last reviewed 2025-12-26 · How we verify

NCT04760704: MONITOCOVAGING

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Covid-19 Vaccine Response in Elderly Subjects

Completed Last updated 26 December 2025

What this trial tests

trial testing Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration in Covid19 Vaccine in 264 participants. Completed in 28 March 2023.

Timeline

18 February 2021

Primary endpoint
28 March 2023

28 March 2023

Quick facts

Lead sponsor	University Hospital, Lille
Status	Completed
Study type	OBSERVATIONAL
Enrollment	264
Start date	18 February 2021
Primary completion	28 March 2023
Estimated completion	28 March 2023
Sites	1 location across France

Drugs / interventions tested

Specific antibody and cellular immune response after anti-SARS-CoV-2 vaccine administration — full drug profile →

Conditions studied

Covid19 Vaccine — all drugs for Covid19 Vaccine →

Sponsor

University Hospital, Lille

Who can join

40 and older, any sex, with Covid19 Vaccine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this research is to assess the amplitude and quality of the vaccine response against SARS-CoV-2, defined here by its characteristics established at 3 months, and its persistence over time, defined here at 9 months, in subjects residing in medical establishment for dependent elderly persons, compared to immunocompetent subjects aged 40 to 65 years (control subjects for vaccination over the same period).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
Demaret J, Corroyer-Simovic B, Alidjinou EK, Goffard A, et al · · 2021 · cited 66× · PMID 34868051 · DOI 10.3389/fimmu.2021.778679
Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years.
Alidjinou EK, Demaret J, Corroyer-Simovic B, Labreuche J, et al · · 2022 · cited 19× · PMID 35469147 · DOI 10.1016/j.lanepe.2022.100385
Evolution of Blood Innate Immune Cell Phenotypes Following SARS-CoV-2 Infection in Hospitalized Patients with COVID-19.
Dendooven A, Esnault S, Jacob M, Trauet J, et al · · 2025 · PMID 40710346 · DOI 10.3390/cells14141093
Immunogenicity of a BNT162b2 Vaccine Booster Against SARS-CoV-2 Delta and Omicron Variants in Older People
Alidjinou EK, Demaret J, Corroyer-Simovic B, Labreuche J, et al · · 2022 · DOI 10.2139/ssrn.4037259

Verify or expand the search:

Other University Hospital, Lille trials

Trials by the same sponsor.

NCT07528664 — Assessement of a Test a Financial-incentive Program for Pregnant Women and Their Smoking Partners to Reduce Smoking Duri · NA · not yet recruiting
NCT07434739 — PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies · NA · not yet recruiting
NCT06958224 — Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers · NA · not yet recruiting
NCT07408999 — Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer · NA · not yet recruiting
NCT07492030 — Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04760704 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Lille
Last refreshed: 26 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04760704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing